273 related articles for article (PubMed ID: 17258718)
1. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
6. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
7. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
8. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
[TBL] [Abstract][Full Text] [Related]
9. Long-term risk of ischemic stroke associated with rofecoxib.
Afilalo J; Coussa-Charley MJ; Eisenberg MJ
Cardiovasc Drugs Ther; 2007 Apr; 21(2):117-20. PubMed ID: 17393291
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
12. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Hawkey CJ; Laine L; Harper SE; Quan HU; Bolognese JA; Mortensen E;
Aliment Pharmacol Ther; 2001 Oct; 15(10):1593-601. PubMed ID: 11563999
[TBL] [Abstract][Full Text] [Related]
13. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
[TBL] [Abstract][Full Text] [Related]
14. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
Schneeweiss S; Glynn RJ; Avorn J; Mamdani M; Mogun H; Solomon DH
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1134-42. PubMed ID: 19844943
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
16. [Safety of specific cyclo-oxygenase 2 inhibitors].
Lems WF; van de Laar MA; Bijlsma JW
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1044-7. PubMed ID: 11414163
[TBL] [Abstract][Full Text] [Related]
17. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
18. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
Baron JA; Sandler RS; Bresalier RS; Lanas A; Morton DG; Riddell R; Iverson ER; Demets DL
Lancet; 2008 Nov; 372(9651):1756-64. PubMed ID: 18922570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
